Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy
Open Access
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 26 (1) , 231-237
Abstract
Background The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2013 to provide a set of specific recommendations regarding patient-reported outcomes (PROs) reporting in randomized clinical trials (RCTs). There is limited data regarding how well current publications of oncology RCTs report PROs if assessed using these guidelines. Design All phase III medical oncology RCTs published between 2007 and 2011 were reviewed according to the 2013 PROs CONSORT recommendations and a 11-point PROs reporting quality score (PRORQS) was defined based on the criteria. Results The majority of trials did not report on PROs at all (201 of 325; 62%). Of the remaining 124 trials, the mean PRORQS score was 5.0 on an 11 points scale. The items related to methods of PROs collection and analysis were poorly reported (Description of the prespecified PRO hypothesis : 26% of RCTs ; methods for PRO data collection (paper, telephone, electronic, other) : 16% ; statistical approaches for managing missing data : 37%). The only factor significantly associated with improved PROs reporting was where PROs reporting was the subject of a dedicated secondary manuscript, as was the case in 36 of the 124 (29%) of RCTs. Conclusion Despite their clinical relevance, our findings show that some aspects of PROs reporting may greatly be improved, especially critical methodological aspects of PROs collection and analysis. The exceptions were where PROs were described in PROs-specific secondary publication. Use of the 2013 PROs CONSORT extensions should be encouraged and their effects on PROs reporting subsequently reassessed.Keywords
This publication has 14 references indexed in Scilit:
- The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practiceHealth and Quality of Life Outcomes, 2013
- Patient-reported outcomes in meta-analyses – Part 1: assessing risk of bias and combining outcomesHealth and Quality of Life Outcomes, 2013
- The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer DrugsJournal of Clinical Oncology, 2012
- Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic ReviewJNCI: Journal of the National Cancer Institute, 2012
- A Review of Patient-Reported Outcome Labels in the United States: 2006 to 2010Value in Health, 2012
- Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchersQuality of Life Research, 2010
- The Missing Voice of Patients in Drug-Safety ReportingNew England Journal of Medicine, 2010
- Using patient-reported outcomes in clinical practice: challenges and opportunitiesQuality of Life Research, 2008
- Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision makingAnnals of Oncology, 2007
- Publication bias in clinical researchThe Lancet, 1991